GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?
This article was originally published in PharmAsia News
Executive Summary
In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14
You may also be interested in...
China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.
Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue
Merck is including its vaccine distribution partner Chongqing Zhifei in its development plan for at least two vaccines in China, while global firms regain a footing after new standards in the Chinese Pharmacopeia stilted their market growth.
Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue
Merck is including its vaccine distribution partner Chongqing Zhifei in its development plan for at least two vaccines in China, while global firms regain a footing after new standards in the Chinese Pharmacopeia stilted their market growth.